Dexcel Pharma

Dexcel Pharma is the largest private pharmaceutical company in Israel, renowned for its extensive portfolio of branded and generic drugs. Founded in 1968, the company has grown into a global player, with state-of-the-art R&D and manufacturing facilities that support the development and commercialization of innovative and cost-effective pharmaceutical products. Dexcel's product portfolio spans across various therapeutic areas, including small molecules, biologics, and RNA-based therapies. The company is committed to advancing science through substantial investments in R&D, particularly in cutting-edge fields like siRNA therapeutics and oligonucleotides. Their innovation initiatives include the creation of specialized entities like Dexoligo Therapeutics, which focuses on RNA-based medicines, and Clexio Biosciences, which develops treatments for neurological and psychiatric conditions. With over 1,200 employees and a strong presence in key markets like the United States, Germany, and the UK, Dexcel manufactures over 5 billion oral-solid dosages annually. The company maintains a reputation for quality, with its facilities meeting global standards and holding approvals from regulatory bodies like the FDA and EMA.